Literature DB >> 12928225

Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma.

Jolanta Szenajch1, Bogdan Jasiński, Agnieszka Synowiec, Jadwiga Kulik, Małgorzata Chomicka, Jerzy Struzyna, Zbigniew Nowecki, Piotr Rutkowski, Włodzimierz Ruka, Witold Kupść, Janusz A Siedlecki, Wiesław Wiktor-Jedrzejczak.   

Abstract

BACKGROUND: The reverse transcription-PCR tyrosinase assay (TYR test) cannot reliably detect malignant melanoma (MM) cells in blood as the cells often circulate at low concentrations. We evaluated the prognostic value of multiple TYR testing, the prognostic significance of individual positive TYR test results (TYR+) in asymptomatic melanoma patients, and whether statistical analysis could help in the interpretation of results of a test that measures phenomena that typically occur below its detection threshold.
METHODS: MM patients in stages I-IV (n = 150) underwent multiple testing with the TYR test during the course of their disease. TYR testing was performed as described by Smith et al. (Lancet 1991;38:1227-9). Statistical analyses were performed with the logistic function and t-test procedures.
RESULTS: The relationship between MM stage and the frequency of TYR+ was statistically significant (P = 0.011). Higher frequency of TYR+ in clinically asymptomatic patients after complete resection of the primary tumor was associated with an increased risk of recurrence of MM (prognostic sensitivity, 62%; specificity, 78%).
CONCLUSIONS: A single positive TYR test provides a warning for disease relapse, suggesting that multiple TYR testing might provide more reliable predictions of disease progression. Multiple testing and statistical analysis using a logistic function might allow for the interpretation of apparently inconsistent results of tests for very rare cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928225     DOI: 10.1373/49.9.1450

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

Review 1.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

2.  Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.

Authors:  Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka
Journal:  Ann Surg Oncol       Date:  2010-07-07       Impact factor: 5.344

3.  Prognostic significance of melanoma differentiation and trans-differentiation.

Authors:  Nityanand Maddodi; Vijayasaradhi Setaluri
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

4.  Anticancer properties of peptide fragments of hair proteins.

Authors:  Sergiusz Markowicz; Joanna Matalinska; Katarzyna Kurzepa; Marta Bochynska; Marzena Biernacka; Anna Samluk; Dorota Dudek; Henryk Skurzak; Masaaki Yoshikawa; Andrzej W Lipkowski
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.